Home » Exelixis Achieves $35 Million in Milestones From GSK
Exelixis Achieves $35 Million in Milestones From GSK
Exelixis, Inc. announced that it has achieved two milestones totaling $35 million under its collaboration agreement with GlaxoSmithKline (GSK). The first of these milestones, totaling $30 million, was achieved as a result of the submission of the investigational new drug (INDs) applications for XL880 in December 2004, and XL820 and XL844 in April 2005.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-09-2005/0003589429&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
07May
-
14May
-
30May